ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Albany Molecular advances a compound

November 6, 2006 | APPEARED IN VOLUME 84, ISSUE 45

Contract research firm Albany Molecular Research Inc. (AMRI) hopes to file an Investigational New Drug Application next year for a compound in its oncology research program. In preclinical disease models, the candidate, a novel analog of an established class of tubulin inhibitors, showed greater efficacy than marketed members of the class in killing cancer cells, according to AMRI. This is the second time AMRI has advanced early-stage candidates. In 2005, the firm selected two compounds from its biogenic amines program for advanced preclinical trials. The compounds, still in development, were subsequently licensed to Bristol-Myers Squibb.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment